EMEA-002597-PIP09-22 - paediatric investigation plan
Efgartigimod alfa
PIPHuman
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Argenx BV
E-mail: regulatory@argenx.com
Tel: +32 93103400